Phase I study of 2'-deoxycoformycin in acute lymphoblastic leukemia.

David G. Poplack(National Institutes of Health), David G. Johns, Richard S. Ungerleider(Theradex Oncology (United States)), Jeffrey M. Lipton(Feinstein Institute for Medical Research), Stephen E. Sallan, Peter Venner(Cancer Institute (WIA)), John S. Holcenberg(Children's of Alabama), Daniel Glaubiger(National Institutes of Health), Gaston K. Rivera(St. Jude Children's Research Hospital), Sharon B. Murphy, Julie Blatt(Center for Cancer and Blood Disorders)
PubMed
September 1, 1981
Cited by 87

Related Papers

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
|Journal of Clinical Oncology|1996|1.6k
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
|New England Journal of Medicine|1999|1.2k
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|914
Development of Risk-Based Guidelines for Pediatric Cancer Survivors: The Children's Oncology Group Long-Term Follow-Up Guidelines From the Children's Oncology Group Late Effects Committee and Nursing Discipline
|Journal of Clinical Oncology|2004|709